Total protocols 469 | COVID-19 | No COVID-19 | p value |
---|---|---|---|
N (%) | 208 (44.3) | 261 (55.7) | 0.016 |
Study design | |||
Interventional study | 17 (8.2) | 48 (18.4) | 0.001 |
Observational study | 162 (77.9) | 161 (61.7) | 0.000 |
Qualitative study | 18 (8.7) | 34 (13.0) | 0.134 |
Othersa | 11 (5.3) | 18 (6.9) | 0.473 |
Funding | |||
External/Public grant | 47 (22.6) | 37 (14.2) | 0.018 |
Internal grant | 7 (3.4) | 12 (4.6) | 0.501 |
Private funding | 33 (15.9) | 64 (24.5) | 0.021 |
No funding | 121 (58.2) | 148 (56.7) | 0.749 |
PI characteristics | |||
Gender (Female) | 122 (58.7) | 174 (66.7) | 0.002 |
Holds a PhD degree (yes) | 86 (41.3) | 88 (33.7) | 0.019 |
Research group membership (yes) | 74 (35.6) | 61 (23.4) | 0.004 |
Professionals | |||
General Practitioners (GP) | 100 (48.1) | 91 (34.9) | 0.004 |
Physicians other than GP | 34 (16.3) | 33 (12.6) | 0.255 |
Pediatricians | 7 (3.4) | 6 (2.3) | 0.485 |
Physicians (Gynecologist) | 0 (0.0) | 6 (2.3) | 0.008 |
Nurse | 29 (13.9) | 66 (25.3) | 0.002 |
Other health professionals | 10 (4.8) | 14 (5.4) | 0.786 |
Pharmacists | 6 (2.9) | 10 (3.8) | 0.575 |
Biostatisticians/IT | 2 (1.0) | 3 (1.1) | 0.844 |
Others | 4 (1.9) | 10 (3.8) | 0.228 |
Unknown | 16 (7.7) | 22 (8.4) | 0.771 |
EC Results | |||
Approval | 175 (84.1) | 209 (80.1 | 0.257 |
Days until approval | |||
0 | 46 (26.3) | 57 (27.3) | 0.828 |
1–30 | 16 (9.1) | 54 (25.8) | 0.009 |
31–90 | 67 (38.3) | 65 (31.1) | 0.197 |
91–180 | 44 (25.1) | 28 (13.4) | 0.192 |
> 6 months | 2 (1.1) | 5 (2.4) | 0.362 |
Modification required | 32 (15.4) | 49 (18.8) | 0.335 |
Withdrawn | 1 (0.5) | 2 (0.8) | 0.696 |
Denied | 0 (0.0) | 1 (0.4) | 0.279 |
Days to be approved (mean, SD) | 33.3 (45.0) | 40.1 (52.1) | 0.101 |